Cargando…

Accidental Ixazomib Overdose in a Patient With Multiple Myeloma

Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of oral chemotherapeutic agents for the managemen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sampat, Parth J., Bisen, Maneesh, Srivastava, Nimisha, Rao, Suman, Gentile, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127745/ https://www.ncbi.nlm.nih.gov/pubmed/33980053 http://dx.doi.org/10.1177/23247096211013230

Ejemplares similares

An Unusual Case of Ventricular Tachycardia in a Young Patient Associated with Cannabis Use
por: Sampat, Parth J., et al.
Publicado: (2020)

T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
por: Haq, M., et al.
Publicado: (2021)

Accidental Overdose of Multiple Chemotherapeutic Agents
por: Kim, In Soon, et al.
Publicado: (1989)

An Uncommon Presentation of DRESS Syndrome Secondary to Leflunomide Use: A Case Report
por: Rao, Suman, et al.
Publicado: (2021)

Accidental Overdose of Paliperidone Palmitate
por: Ojimba, Chiedozie, et al.
Publicado: (2019)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Hydroxycarbamide overdose: Marrow suppression presenting as neutropenia following accidental overdose: case report
Publicado: (2020)

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
por: Kumar, Shaji K., et al.
Publicado: (2019)

Accidental staggered paracetamol overdose: An interesting case report
por: Aabideen, Kanakkande, et al.
Publicado: (2011)

Therapeutic Challenges with Catastrophic Antiphospholipid Antibody Syndrome: A Case Report
por: Harne, Prateek, et al.
Publicado: (2020)

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma
por: Bühler, Selina, et al.
Publicado: (2023)

A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma
por: Katz, Heather, et al.
Publicado: (2019)

Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose
por: Ballesta Méndez, Maria, et al.
Publicado: (2014)

Cardiac arrest due to accidental overdose with norepinephrine dissolved in crystalloid
por: Hansel, Jan, et al.
Publicado: (2020)

Treatment of concurrent etizolam and tianeptine withdrawal following accidental overdose
por: Markovic, Marija, et al.
Publicado: (2023)

Ivermectin overdose and misuse: Acute encephalopathy due to accidental overdose following drug misuse: case report
Publicado: (2021)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
por: Kumar, S K, et al.
Publicado: (2015)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
por: Li, Shutan, et al.
Publicado: (2022)

New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
por: Richardson, Paul G, et al.
Publicado: (2017)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
por: Manda, Sudhir, et al.
Publicado: (2020)

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2018)

Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report
por: Jin, Fengbo, et al.
Publicado: (2020)

An Uncommon Incidence of Pulmonary Hypertension Associated With Neurofibromatosis Type 1: A Case Report
por: Rao, Suman, et al.
Publicado: (2021)

Flecainide Toxicity Secondary to Accidental Overdose: A Pediatric Case Report of Two Brothers
por: Gardner Yelton, Sarah E., et al.
Publicado: (2021)

An accidental liraglutide overdose: case report
por: Elmehdawi, Rafik R., et al.
Publicado: (2014)

Dangerous mistake: an accidental caffeine overdose
por: Andrade, Ana, et al.
Publicado: (2018)

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2019)

P978: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR PATIENTS WITH MULTIPLE MYELOMA: INTERIM ANALYSIS OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA
por: Zhuang, Z., et al.
Publicado: (2022)

Accidental Rivaroxaban Overdose in a Patient with Pulmonary Embolism: Some Lessons for Managing New Oral Anticoagulants
por: Sajkov, Dimitar, et al.
Publicado: (2015)

Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program
por: Varga, Gergely, et al.
Publicado: (2019)

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
por: Kumar, Shaji K., et al.
Publicado: (2018)

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
por: Mina, Roberto, et al.
Publicado: (2021)

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
por: Offidani, Massimo, et al.
Publicado: (2014)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
por: Kumar, Shaji, et al.
Publicado: (2017)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
por: Groen, Kazimierz, et al.
Publicado: (2023)

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
por: Patel, Krina K., et al.
Publicado: (2022)

P873: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: UPDATE OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA
por: Zhuang, Zhe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l47or39731tasqsehesm4jina1